ILLUCCIX Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Illuccix, and when can generic versions of Illuccix launch?
Illuccix is a drug marketed by Telix and is included in one NDA. There is one patent protecting this drug.
This drug has forty-two patent family members in eighteen countries.
The generic ingredient in ILLUCCIX is gallium ga-68 gozetotide. There are sixteen drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the gallium ga-68 gozetotide profile page.
DrugPatentWatch® Generic Entry Outlook for Illuccix
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be July 28, 2035. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ILLUCCIX?
- What are the global sales for ILLUCCIX?
- What is Average Wholesale Price for ILLUCCIX?
Summary for ILLUCCIX
| International Patents: | 42 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Clinical Trials: | 2 |
| Drug Prices: | Drug price information for ILLUCCIX |
| What excipients (inactive ingredients) are in ILLUCCIX? | ILLUCCIX excipients list |
| DailyMed Link: | ILLUCCIX at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for ILLUCCIX
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for ILLUCCIX
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Telix International Pty Ltd | Phase 3 |
| Grand Pharmaceutical (China) Co., Ltd. | Phase 3 |
| BAMF Health | Early Phase 1 |
US Patents and Regulatory Information for ILLUCCIX
ILLUCCIX is protected by one US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of ILLUCCIX is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting ILLUCCIX
Kit for radiolabelling
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: POSITRON EMISSION TOMOGRAPHY (PET) OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) POSITIVE LESIONS IN MEN WITH PROSTATE CANCER
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Telix | ILLUCCIX | gallium ga-68 gozetotide | POWDER;INTRAVENOUS | 214032-001 | Dec 17, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for ILLUCCIX
When does loss-of-exclusivity occur for ILLUCCIX?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 15309187
Patent: Kit for radiolabelling with 68GA comprising a metal inhibitor
Estimated Expiration: ⤷ Sign Up
Patent: 15309188
Patent: Mono-, di- or polysaccharide used as metal inhibitor in the preparation of 68Ga-chelate-functionalized targeting agent
Estimated Expiration: ⤷ Sign Up
Patent: 20220193
Patent: Kit for radiolabelling with 68GA comprising a metal inhibitor
Estimated Expiration: ⤷ Sign Up
Patent: 20220194
Patent: Mono-,di- or polysaccharide used as metal inhibitor in the preparation of 68Ga-chelate-functionalized targeting agent
Estimated Expiration: ⤷ Sign Up
Patent: 22202346
Patent: Kit for radiolabelling with 68GA comprising a metal inhibitor
Estimated Expiration: ⤷ Sign Up
Patent: 22202439
Patent: Mono-,di- or polysaccharide used as metal inhibitor in the preparation of 68Ga-chelate-functionalized targeting agent
Estimated Expiration: ⤷ Sign Up
Belgium
Patent: 21191
Patent: KIT POUR RADIOMARQUAGE.
Estimated Expiration: ⤷ Sign Up
Brazil
Patent: 2017003578
Patent: kit para radiomarcação com 68ga compreendendo um inibidor de metal
Estimated Expiration: ⤷ Sign Up
Patent: 2017003710
Patent: mono-, di- ou polissacarídeo usado como inibidor de metal na preparação de agente de direcionamento com grupamento funcional de 68ga-quelato
Estimated Expiration: ⤷ Sign Up
Patent: 2021017474
Patent: Método para radiomarcação de um agente de direcionamento com grupamento funcional de quelato com um radionuclídeo de metal, e kit para radiomarcação
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 58471
Patent: KIT POUR LE RADIOMARQUAGE AU 68GA COMPRENANT UN INHIBITEUR METALLIQUE (KIT FOR RADIOLABELLING WITH 68GA COMPRISING A METAL INHIBITOR)
Estimated Expiration: ⤷ Sign Up
Patent: 58475
Patent: MONO-, DI- OU OLIGOSIDE UTILISE COMME INHIBITEURS METALLIQUES DANS LA PREPARATION D'AGENTS CIBLES FONCTIONNALISES METAL-CHELATE (MONO-, DI- OR OLIGOSACCHARIDE USED AS METAL INHIBITORS IN THE PREPARATION OF RADIOACTIVE METAL-CHELATE-FUNCTIONALIZED TARGET AGENTS)
Estimated Expiration: ⤷ Sign Up
Patent: 67294
Patent: MONO-, DI- OU POLYSACCHARIDE UTILISE COMME INHIBITEUR METALLIQUE DANS LAPREPARATION D'AGENTS CIBLES FONCTIONNALISES DU CHELATE 68GA (MONO-, DI- OR POLYSACCHARIDE USED AS METAL INHIBITOR IN THE PREPARATION OF 68GA-CHELATE-FUNCTIONALIZED TARGETING AGENT)
Estimated Expiration: ⤷ Sign Up
China
Patent: 6659806
Patent: 在制备68GA‑螯合物官能化的靶向剂中用作金属抑制剂的单糖、二糖或多糖 (Mono-, di- or polysaccharide used as metal inhibitor in the preparation of 68GA-chelate-functionalized targeting agent)
Estimated Expiration: ⤷ Sign Up
Patent: 6794265
Patent: 用于使用68GA放射性标记的含金属抑制剂的试剂盒 (Kit for radiolabelling with 68ga comprising a metal inhibitor)
Estimated Expiration: ⤷ Sign Up
Denmark
Patent: 85911
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 85911
Patent: KIT POUR LE RADIOMARQUAGE AU 68GA COMPRENANT UN INHIBITEUR MÉTALLIQUE (KIT FOR RADIOLABELLING WITH 68GA COMPRISING A METAL INHIBITOR)
Estimated Expiration: ⤷ Sign Up
Patent: 85912
Patent: MONOSACCHARIDE, DISACCHARIDE OU POLYSACCHARIDE UTILISÉ COMME INHIBITEUR DE MÉTAL DANS LA PRÉPARATION DE D'AGENT DE CIBLAGE FONCTIONNALISÉ PAR DU 68GA-CHÉLATE (MONO-, DI- OR POLYSACCHARIDE USED AS METAL INHIBITOR IN THE PREPARATION OF 68GA-CHELATE-FUNCTIONALIZED TARGETING AGENT)
Estimated Expiration: ⤷ Sign Up
Patent: 62025
Patent: KIT POUR LE RADIOMARQUAGE AU 68GA COMPRENANT UN INHIBITEUR MÉTALLIQUE (KIT FOR RADIOLABELLING WITH 68GA COMPRISING A METAL INHIBITOR)
Estimated Expiration: ⤷ Sign Up
Patent: 62026
Patent: MONOSACCHARIDE, DISACCHARIDE OU POLYSACCHARIDE UTILISÉ COMME INHIBITEUR DE MÉTAL DANS LA PRÉPARATION DE D'AGENT DE CIBLAGE FONCTIONNALISÉ PAR DU 68GA-CHÉLATE (MONO-, DI- OR POLYSACCHARIDE USED AS METAL INHIBITOR IN THE PREPARATION OF 68GA-CHELATE-FUNCTIONALIZED TARGETING AGENT)
Estimated Expiration: ⤷ Sign Up
Hungary
Patent: 53971
Estimated Expiration: ⤷ Sign Up
Israel
Patent: 0735
Patent: חד-, דו- או פוליסכאריד המשמש כמעכב מתכת בהכנה של ga68-קלאט-גורם ממקד משופעל (Mono-, di- or polysaccharide used as metal inhibitor in the preparation of 68ga-chelate-functionalized targeting agent)
Estimated Expiration: ⤷ Sign Up
Patent: 0736
Patent: ערכה עבור התוויה רדיואקטיבית עם ga68 המכיל מעכב מתכת (Kit for radiolabelling with 68ga comprising a metal inhibitor)
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 43343
Estimated Expiration: ⤷ Sign Up
Patent: 52622
Estimated Expiration: ⤷ Sign Up
Patent: 17526745
Patent: 金属阻害剤
Estimated Expiration: ⤷ Sign Up
Patent: 17530188
Patent: 放射標識用キット
Estimated Expiration: ⤷ Sign Up
Mexico
Patent: 17002361
Patent: MONO-, DI-, O POLISACARIDO USADO COMO INHIBIDOR DE METAL EN LA PREPARACION DEL AGENTE ENFOCADO FUNCIONALIZADO CON QUELATO GALIO 68 (68GA). (MONO-, DI- OR POLYSACCHARIDE USED AS METAL INHIBITOR IN THE PREPARATION OF 68GA-CHELATE-FUNCTIONALIZED TARGETING AGENT.)
Estimated Expiration: ⤷ Sign Up
Patent: 17002362
Patent: KIT PARA MARCAJE RADIACTIVO CON GALIO 68 (68GA) QUE COMPRENDE UN INHIBIDOR DE METAL. (KIT FOR RADIOLABELLING WITH 68GA COMPRISING A METAL INHIBITOR.)
Estimated Expiration: ⤷ Sign Up
New Zealand
Patent: 9291
Patent: Kit for radiolabelling with 68ga comprising a metal inhibitor
Estimated Expiration: ⤷ Sign Up
Patent: 9293
Patent: Mono-, di- or polysaccharide used as metal inhibitor in the preparation of 68ga-chelate-functionalized targeting agent
Estimated Expiration: ⤷ Sign Up
Poland
Patent: 85911
Estimated Expiration: ⤷ Sign Up
Portugal
Patent: 85911
Estimated Expiration: ⤷ Sign Up
Russian Federation
Patent: 24894
Patent: НАБОР ДЛЯ МЕЧЕНИЯ РАДИОАКТИВНЫМИ ИЗОТОПАМИ (RADIO-ISOTOPE LABELING KIT)
Estimated Expiration: ⤷ Sign Up
Patent: 25627
Patent: ИНГИБИТОР МЕТАЛЛОВ (METAL INHIBITOR)
Estimated Expiration: ⤷ Sign Up
Patent: 17109582
Patent: ИНГИБИТОР МЕТАЛЛОВ
Estimated Expiration: ⤷ Sign Up
Patent: 17109583
Patent: НАБОР ДЛЯ МЕЧЕНИЯ РАДИОАКТИВНЫМИ ИЗОТОПАМИ
Estimated Expiration: ⤷ Sign Up
South Africa
Patent: 1702152
Patent: KIT FOR RADIOLABELLING WITH 68GA COMPRISING A METAL INHIBITOR
Estimated Expiration: ⤷ Sign Up
Spain
Patent: 55991
Estimated Expiration: ⤷ Sign Up
Patent: 56030
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering ILLUCCIX around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Japan | 2017530188 | 放射標識用キット | ⤷ Sign Up |
| Russian Federation | 2017109583 | НАБОР ДЛЯ МЕЧЕНИЯ РАДИОАКТИВНЫМИ ИЗОТОПАМИ | ⤷ Sign Up |
| Denmark | 3185911 | ⤷ Sign Up | |
| Mexico | 2017002362 | KIT PARA MARCAJE RADIACTIVO CON GALIO 68 (68GA) QUE COMPRENDE UN INHIBIDOR DE METAL. (KIT FOR RADIOLABELLING WITH 68GA COMPRISING A METAL INHIBITOR.) | ⤷ Sign Up |
| Brazil | 112017003710 | mono-, di- ou polissacarídeo usado como inibidor de metal na preparação de agente de direcionamento com grupamento funcional de 68ga-quelato | ⤷ Sign Up |
| Brazil | 122021017474 | Método para radiomarcação de um agente de direcionamento com grupamento funcional de quelato com um radionuclídeo de metal, e kit para radiomarcação | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
